Related references
Note: Only part of the references are listed.Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease
Philip S. J. Weston et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Defining pre-symptomatic amyotrophic lateral sclerosis
Michael Benatar et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2019)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease
Oliver Preische et al.
NATURE MEDICINE (2019)
Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
Maxim De Schaepdryver et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
Nina Rostgaard et al.
NEUROLOGY (2018)
Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion
Michael Benatar et al.
ANNALS OF NEUROLOGY (2018)
A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry
Elisabetta Zucchi et al.
JOURNAL OF NEUROCHEMISTRY (2018)
Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers
Lieke H. H. Meeter et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
Lauren M. Byrne et al.
LANCET NEUROLOGY (2017)
Serum neurofilament light in familial Alzheimer disease A marker of early neurodegeneration
Philip S. J. Weston et al.
NEUROLOGY (2017)
Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
Koen Poesen et al.
NEUROLOGY (2017)
Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria
Michael J. Strong et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2017)
Neurofilament Levels as Biomarkers in Asymptomatic and Symptomatic Familial Amyotrophic Lateral Sclerosis
Patrick Weydt et al.
ANNALS OF NEUROLOGY (2016)
Neurofilament light chain: a biomarker for genetic frontotemporal dementia
Lieke H. Meeter et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease
Tua Vinther-Jensen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2016)
Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
Ching-Hua Lu et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Cerebrospinal Fluid Neurofilament Concentration Reflects Disease Severity in Frontotemporal Degeneration
Carole S. Scherling et al.
ANNALS OF NEUROLOGY (2014)
Symptom onset in autosomal dominant Alzheimer disease A systematic review and meta-analysis
Davis C. Ryman et al.
NEUROLOGY (2014)
The A4 Study: Stopping AD Before Symptoms Begin?
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Screening for cognition and behaviour changes in ALS
Sharon Abrahams et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2014)
Presymptomatic studies in ALS Rationale, challenges, and approach
Michael Benatar et al.
NEUROLOGY (2012)
CAG-Repeat Length and the Age of Onset in Huntington Disease (HD): A Review and Validation Study of Statistical Approaches
Douglas R. Langbehn et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS (2010)
Plasma neurofilament heavy chain levels in Huntington's disease
Edward J. Wild et al.
NEUROSCIENCE LETTERS (2007)
Preventing familial amyotrophic lateral sclerosis: Is a clinical trial feasible?
Michael Benatar et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
Share Paper
